C-REACTIVE PROTEIN RANDOMIZED TRIALS AS PREDICTORS FOR USEFULNESS OF ASPIRIN v. MI, SUGGESTED BY STUDY; CRP ASSAY STUDY BY BEHRING MAY BE PUBLISHED IN 1998
This article was originally published in The Gray Sheet
Executive Summary
Inflammatory markers such as C-reactive protein should be studied in randomized trials for their utility in providing a method of "identifying people for whom aspirin is likely to be more or less effective" for reducing the risk of myocardial infarction, Paul Ridker, MD, Brigham & Women's Hospital, Boston, et al., state in a study published in the April 3 New England Journal of Medicine.
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.